Targeting the NLRP3 inflammasome in cardiovascular diseases

S Toldo, E Mezzaroma, LF Buckley, N Potere… - Pharmacology & …, 2022 - Elsevier
The NACHT, leucine-rich repeat (LRR), and pyrin domain (PYD)-containing protein 3
(NLRP3) inflammasome is an intracellular sensing protein complex that plays a major role in …

Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease

A Abbate, S Toldo, C Marchetti, J Kron… - Circulation …, 2020 - Am Heart Assoc
The intracellular sensing protein termed NLRP3 (for NACHT, LRR, and PYD domains-
containing protein 3) forms a macromolecular structure called the NLRP3 inflammasome …

SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease

SR Kim, SG Lee, SH Kim, JH Kim, E Choi… - Nature …, 2020 - nature.com
Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular events
in humans with type 2 diabetes (T2D); however, the underlying mechanism remains unclear …

Targeting early atherosclerosis: a focus on oxidative stress and inflammation

P Marchio, S Guerra-Ojeda, JM Vila… - Oxidative medicine …, 2019 - Wiley Online Library
Atherosclerosis is a chronic vascular inflammatory disease associated to oxidative stress
and endothelial dysfunction. Oxidation of low‐density lipoprotein (LDL) cholesterol is one of …

Inflammasomes as therapeutic targets in human diseases

Y Li, H Huang, B Liu, Y Zhang, X Pan, XY Yu… - Signal transduction and …, 2021 - nature.com
Inflammasomes are protein complexes of the innate immune system that initiate
inflammation in response to either exogenous pathogens or endogenous danger signals …

Vascular inflammation and oxidative stress: major triggers for cardiovascular disease

S Steven, K Frenis, M Oelze, S Kalinovic… - Oxidative medicine …, 2019 - Wiley Online Library
Cardiovascular disease is a leading cause of death and reduced quality of life, proven by
the latest data of the Global Burden of Disease Study, and is only gaining in prevalence …

Inflammation in Heart Failure: JACC State-of-the-Art Review

SP Murphy, R Kakkar, CP McCarthy… - Journal of the American …, 2020 - jacc.org
It has long been observed that heart failure (HF) is associated with measures of systemic
inflammation. In recent years, there have been significant advancements in our …

[HTML][HTML] Antiinflammatory therapy with canakinumab for atherosclerotic disease

PM Ridker, BM Everett, T Thuren… - New England journal …, 2017 - Mass Medical Soc
Background Experimental and clinical data suggest that reducing inflammation without
affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory …

An overview and update on obesity and the obesity paradox in cardiovascular diseases

A Elagizi, S Kachur, CJ Lavie, S Carbone… - Progress in …, 2018 - Elsevier
Obesity increases a number of cardiovascular disease (CVD) risk factors, but patients with
many types of CVD may have a better prognosis if classified as overweight or obese, a …

Obesity paradox in cardiovascular disease: where do we stand?

S Carbone, JM Canada, HE Billingsley… - Vascular health and …, 2019 - Taylor & Francis
Obesity is associated with an increased risk of developing cardiovascular disease (CVD),
particularly heart failure (HF) and coronary heart disease (CHD). The mechanisms through …